StockNews.AI
ASRT
StockNews.AI
167 days

Assertio Holdings, Inc. to Report Fourth Quarter and Full Year 2024 Financial Results on March 12, 2025

1. ASRT will release Q4 2024 earnings on March 12, 2025. 2. A live webcast following the earnings release is scheduled for 4:30 PM ET. 3. The company focuses on oncology, neurology, and pain management products.

Earnings
-0.89%Current Return
VS
-1.77%S&P 500
$0.817303/05 04:07 PM EDTEvent Start
$0.8103/06 10:08 PM EDTLatest Updated
3m saved
Insight
Article

FAQ

Why Neutral?

The earnings announcement typically has mixed market reactions depending on results. Historical data shows no major price shifts from earnings releases alone unless results significantly exceed or fail expectations.

How important is it?

Upcoming earnings can significantly influence investor sentiment and trading volumes. However, without additional context, it remains a standard event with moderate importance.

Why Short Term?

Investors may react swiftly to Q4 results, influencing short-term price movements. Typically, earnings seasons trigger immediate trading volatility.

Related Companies

ROIVEIDXPTGX
LAKE FOREST, Ill., March 05, 2025 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT) today announced that it will release fourth quarter and full year 2024 financial results on Wednesday, March 12, 2025, after the market close. Following the release of its financial results, Assertio’s management will host a live webcast of the earnings conference call at 4:30 p.m. Eastern Time. To access the live webcast, conference call information, and other materials, please visit Assertio’s investor relations website at http://investor.assertiotx.com/overview/default.aspx. Please connect at least 10 minutes prior to the live webcast to ensure adequate time for any software download that may be needed to access the webcast. For those wishing to join by telephone only, please dial +1-646-307-1963. The call ID is 3278948. A webcast replay of the call will be available approximately two hours after the call on Assertio’s investor website. About AssertioAssertio is a pharmaceutical company with comprehensive commercial capabilities offering differentiated products designed to address patients’ needs. Our focus is on supporting patients through marketing such products for oncology, neurology, and pain management. To learn more about Assertio, visit www.assertiotx.com. Investor Contact Matt KrepsDarrow Associates Investor Relations+1-214-597-8200mkreps@darrowir.com

Related News